ReviewMayo Clinic proceedings. Innovations, quality & outcomes2026
Clinical and Genetic Characteristics of Hereditary Arrhythmias and Cardiomyopathies in the Middle East.
Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inherited arrhythmias and cardiomyopathies are leading causes of sudden cardiac death in young individuals. Although global registries and genetic databases have advanced diagnosis and prevention globally, data from the Middle East (ME) remain limited and fragmented. This review synthesizes clinical and genetic evidence on long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy, and dilated cardiomyopathy across the ME. A defining feature of ME cohorts is the high prevalence of consanguinity, which shapes a distinctive genetic and clinical landscape across these conditions. Autosomal recessive inheritance is consistently enriched, producing homozygous genotypes, which frequently manifest as earlier onset and more aggressive clinical phenotypes compared with those in non-ME populations. Population-specific founder variants have been identified across multiple conditions, whereas consanguineous pedigrees have contributed to the discovery of novel disease genes and recessive mechanisms that expand the global genetic landscape of inherited cardiovascular disease. However, a disproportionately high burden of variants of uncertain significance persists across conditions, driven largely by underrepresentation of ME populations in global genomic reference databases. Emerging large-scale genome initiatives such as the Qatar Biobank, the Egyptian Genome Project, and the Greater Middle East Variome offer a viable path toward ancestry-specific variant interpretation. Strengthening regional registries, genomic resources, and family-based screening programs will be essential to improving risk stratification and prevention of sudden cardiac death in the ME.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.